help me understand half-life, I have read the wiki twice
Asking properly rather than in a comment on somebody else’s thread: help me understand half-life, I have read the wiki twice.
The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.
Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Left up and flaired Explainer. This is the standard of post the board was created for.
Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.
dose response is not linear and nobody should assume it is
Cosigning on GIP. The genuinely interesting thing is that the biology is not settled and the clinical result is nonetheless robust.
Is there any human data on that mechanism yet?
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
GIP is the arm people argue about because the biology is genuinely unsettled
Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
tolerance to the gastric effect develops, appetite effect largely persists
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Yes. The central component is the one that explains the reports on this site better than gastric emptying does.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are
nhs_waitlist_n is right that mechanism gives direction and not magnitude. Worth pinning.
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Are we talking about receptor affinity or clinical potency?
mechanism explains a direction, not a magnitude
glucagon agonism sounds paradoxical until you read the energy expenditure work
incretin effect first, then everything else in this board makes sense
Agreed — the incretin effect is the load-bearing concept and everything downstream reads differently once you have it.
mechanism explains a direction, not a magnitude
Agreed — and it is why the central and peripheral stories are complementary rather than rival.
Does the effect persist with continued dosing or does tolerance develop?
- 1Left up and flaired Explainer. This is the standard of post the board was…8 comments in this branch · started by u/incretin_ivy
- 2Careful — you have a plausible mechanism and no evidence that it is the…8 comments in this branch · started by u/marisol_kravchenko